Bone marrow niche adhesion network (BM niche)

The bone marrow niche adhesion network is a complex, multi-component system that regulates the homing, retention, and quiescence of hematopoietic stem cells (HSCs) and various immune cells. It comprises a variety of cell types, including osteoblasts, endothelial cells, and mesenchymal stromal cells, along with extracellular matrix proteins and specialized adhesion molecules like integrins, selectins, and the CXCR4/CXCL12 signaling axis [1][2]. In hematologic malignancies such as leukemia and multiple myeloma, cancer cells hijack this network to find sanctuary from chemotherapy, leading to minimal residual disease and eventual relapse [3]. Therapeutic strategies targeting this network aim to disrupt these protective interactions, thereby mobilizing malignant cells into the peripheral circulation where they are more susceptible to cytotoxic agents [4]. Key molecular targets within this network include CXCR4, VLA-4 (integrin α4β1), and E-selectin, with several inhibitors currently in clinical use or development [5]. Understanding the spatial and temporal dynamics of this network is crucial for improving stem cell transplantation outcomes and overcoming drug resistance in blood cancers [6].

Other names

Hematopoietic stem cell nicheBone marrow microenvironmentEndosteal nicheVascular nicheBM microenvironmental network

Drugs targeting this network typically disrupt the adhesive interactions between hematopoietic stem/progenitor cells (or malignant cells) and the bone marrow stroma, often by antagonizing receptors like CXCR4, VLA-4, or E-selectin to induce mobilization into the peripheral circulation.